Product Highlight - Stelara

The only IL-12/23 biologics for Inflammatory Bowel Disease¹

STELARA^® provides sustained remission for both Crohn’s Disease (CD) and Ulcerative Colitis (UC) patients ^2,3
• Rapid clinical response in 3 weeks and clinical remission in 8 weeks by only 1 intravenous (IV) infusion for CD ⁴
• 5 years sustained remission for CD ² and over 3 years sustained remission data for UC ³
• Mere to placebo safety profile ^4,5 with no increased risk of tuberculosis reactivation and malignancy ^2,5
• Only once IV induction ⁶ and 90 mg subcutaneous (SC) injection at week 8 followed by every 12 weeks 90 mg SC maintenance ⁷

References:
1. Brownstone ND, et al. (2021). Biologics: Targets and Therapy, 39-51. 2. Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. 3. Abreu MT, et al. J Crohns Colitis. 2022 Mar3 [Online ahead of print]. 4. Feagan BG, et al. N Engl J Med. 2016;375(20):1946-1960. 5. Abreu MT, et al. J Crohns Colitis. 2021; 15:S113-S115. 6. STELARA^®IV Hong Kong Prescribing Information P05. 7. STELARA^® Hong Kong Prescribing Information P09.